Coronavirus disease 2019 vaccine hypersensitivity evaluated with vaccine and excipient allergy skin testing

Abstract

Since the coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines became available, Vaccine Adverse Event Reporting System data and early reports identified rare cases of anaphylaxis.1 Banerji et al2 proposed a suggested approach to skin test for COVID-19 vaccine excipients, specifically polyethylene glycol, polysorbate 80, and polysorbate 20. Using this algorithm, and skin testing with COVID-19 mRNA vaccine leftover from vial overfill, we report findings in a case series of 39 patients referred to an allergy and immunology practice for possible COVID-19 vaccine hypersensitivity from January to May 2021.